{"title":"Targeted delivery of chrysin and 5-fluorouracil on MDA-MB-231 cancer cells by a peptide-functionalized L-DOPA-imprinted polymer.","authors":"Sedighe Yosefi, Majid Sirati-Sabet, Abbas Pakdel, Zahra Nabizadeh, Parviz Kokhaei, Hamid Madanchi","doi":"10.1007/s00210-024-03750-z","DOIUrl":null,"url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) is a very aggressive and deadly form of breast cancer for which chemotherapy is the only systemic treatment option. Therefore, novel and more effective targeted or combined therapies, such as specific drug delivery systems that selectively target cancer cells, have received much attention. This research aimed to investigate the effect of targeted delivery of chrysin (CH) and 5-fluorouracil (5FU) using polymer nanoparticles on MDA-MB-231 cells. In this regard, CH and 5FU were individually used as the template to polymerize L-DOPA on the surface of silica nanoparticles. Then, a CD138-targeting peptide was designed for the first time and immobilized on the surface of the polymeric nanocomposite to target TNBC. The results showed that poly(L-DOPA)-CH-peptide and poly(L-DOPA)-5FU-peptide are selective for MDA-MB-231 cells and deliver drugs to them in a targeted manner. In this study, peptide-containing nanocomposites targeting CD138 were more successful in reducing cell proliferation than peptide-free nanocomposites. Also, they increased apoptosis and cell cycle arrest in MDA-MB-231 cancer cells in vitro. The effective and targeted delivery of CH and 5FU to MDA-MB-231 cancer cells by the designed interference peptide in this study can promise an effective treatment method for inhibiting the growth and progression of cancer. However, animal studies are needed to understand the efficacy of the interfering peptide and the final designed construct.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Naunyn-Schmiedeberg's archives of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00210-024-03750-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Triple-negative breast cancer (TNBC) is a very aggressive and deadly form of breast cancer for which chemotherapy is the only systemic treatment option. Therefore, novel and more effective targeted or combined therapies, such as specific drug delivery systems that selectively target cancer cells, have received much attention. This research aimed to investigate the effect of targeted delivery of chrysin (CH) and 5-fluorouracil (5FU) using polymer nanoparticles on MDA-MB-231 cells. In this regard, CH and 5FU were individually used as the template to polymerize L-DOPA on the surface of silica nanoparticles. Then, a CD138-targeting peptide was designed for the first time and immobilized on the surface of the polymeric nanocomposite to target TNBC. The results showed that poly(L-DOPA)-CH-peptide and poly(L-DOPA)-5FU-peptide are selective for MDA-MB-231 cells and deliver drugs to them in a targeted manner. In this study, peptide-containing nanocomposites targeting CD138 were more successful in reducing cell proliferation than peptide-free nanocomposites. Also, they increased apoptosis and cell cycle arrest in MDA-MB-231 cancer cells in vitro. The effective and targeted delivery of CH and 5FU to MDA-MB-231 cancer cells by the designed interference peptide in this study can promise an effective treatment method for inhibiting the growth and progression of cancer. However, animal studies are needed to understand the efficacy of the interfering peptide and the final designed construct.
期刊介绍:
Naunyn-Schmiedeberg''s Archives of Pharmacology was founded in 1873 by B. Naunyn, O. Schmiedeberg and E. Klebs as Archiv für experimentelle Pathologie und Pharmakologie, is the offical journal of the German Society of Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, DGPT) and the Sphingolipid Club. The journal publishes invited reviews, original articles, short communications and meeting reports and appears monthly. Naunyn-Schmiedeberg''s Archives of Pharmacology welcomes manuscripts for consideration of publication that report new and significant information on drug action and toxicity of chemical compounds. Thus, its scope covers all fields of experimental and clinical pharmacology as well as toxicology and includes studies in the fields of neuropharmacology and cardiovascular pharmacology as well as those describing drug actions at the cellular, biochemical and molecular levels. Moreover, submission of clinical trials with healthy volunteers or patients is encouraged. Short communications provide a means for rapid publication of significant findings of current interest that represent a conceptual advance in the field.